全文获取类型
收费全文 | 7051篇 |
免费 | 527篇 |
国内免费 | 58篇 |
专业分类
耳鼻咽喉 | 82篇 |
儿科学 | 189篇 |
妇产科学 | 106篇 |
基础医学 | 1000篇 |
口腔科学 | 188篇 |
临床医学 | 723篇 |
内科学 | 1648篇 |
皮肤病学 | 100篇 |
神经病学 | 655篇 |
特种医学 | 374篇 |
外科学 | 1053篇 |
综合类 | 72篇 |
一般理论 | 5篇 |
预防医学 | 378篇 |
眼科学 | 132篇 |
药学 | 378篇 |
中国医学 | 8篇 |
肿瘤学 | 545篇 |
出版年
2023年 | 51篇 |
2022年 | 42篇 |
2021年 | 171篇 |
2020年 | 138篇 |
2019年 | 170篇 |
2018年 | 210篇 |
2017年 | 152篇 |
2016年 | 171篇 |
2015年 | 208篇 |
2014年 | 287篇 |
2013年 | 357篇 |
2012年 | 539篇 |
2011年 | 514篇 |
2010年 | 351篇 |
2009年 | 295篇 |
2008年 | 478篇 |
2007年 | 474篇 |
2006年 | 407篇 |
2005年 | 394篇 |
2004年 | 322篇 |
2003年 | 313篇 |
2002年 | 277篇 |
2001年 | 61篇 |
2000年 | 45篇 |
1999年 | 71篇 |
1998年 | 75篇 |
1997年 | 67篇 |
1996年 | 73篇 |
1995年 | 69篇 |
1994年 | 63篇 |
1993年 | 62篇 |
1992年 | 39篇 |
1991年 | 37篇 |
1990年 | 36篇 |
1989年 | 52篇 |
1988年 | 63篇 |
1987年 | 46篇 |
1986年 | 39篇 |
1985年 | 32篇 |
1984年 | 36篇 |
1983年 | 33篇 |
1982年 | 40篇 |
1981年 | 38篇 |
1980年 | 25篇 |
1979年 | 21篇 |
1978年 | 20篇 |
1976年 | 15篇 |
1975年 | 19篇 |
1974年 | 18篇 |
1972年 | 13篇 |
排序方式: 共有7636条查询结果,搜索用时 15 毫秒
81.
Afton K. Limberg Meagan E. Tibbo Christopher G. Salib Alex R. McLaury Travis W. Turner Charlotte E. Berry Anthony G. Jay Jodi M. Carter Brad Bolon Daniel J. Berry Mark E. Morrey Joaquin Sanchez-Sotelo Andre J. van Wijnen Matthew P. Abdel 《Journal of orthopaedic research》2020,38(11):2474-2483
The dense formation of abnormal scar tissue after total knee arthroplasty results in arthrofibrosis, an unfortunate sequela of inflammation. The purpose of this study was to use a validated rabbit model to assess the effects on surgically-induced knee joint contractures of two combined pharmacological interventions: celecoxib (CXB) loaded on an implanted collagen membrane, and subcutaneously (SQ) injected ketotifen. Thirty rabbits were randomly divided into five groups. The first group received no intervention after the index surgery. The remaining four groups underwent intra-articular implantation of collagen membranes loaded with or without CXB at the time of the index surgery; two of which were also treated with SQ ketotifen. Biomechanical joint contracture data were collected at 8, 10, 16, and 24 weeks. At the time of necropsy (24 weeks), posterior capsule tissue was collected for messenger RNA and histopathologic analyses. At 24 weeks, there was a statistically significant increase in passive extension among rabbits in all groups treated with CXB and/or ketotifen compared to those in the contracture control group. There was a statistically significant decrease in COL3A1, COL6A1, and ACTA2 gene expression in the treatment groups compared to the contracture control group (P < .001). Histopathologic data also demonstrated a trend towards decreased fibrous tissue density in the CXB membrane group compared to the vehicle membrane group. The present data suggest that intra-articular placement of a treated collagen membrane blunts the severity of contracture development in a rabbit model of arthrofibrosis, and that ketotifen and CXB may independently contribute to the prevention of arthrofibrosis. Statement of clinical significance: Current literature has demonstrated that arthrofibrosis may affect up to 5% of primary total knee arthroplasty patients. For that reason, novel pharmacologic prophylaxis and treatment modalities are critical to mitigating reoperations and revisions while improving the quality of life for patients with this debilitating condition. 相似文献
82.
83.
Angka Leonard Martel Andre B. Ng Juliana Pecarskie Amanda Sadiq Manahil Jeong Ahwon Scaffidi Marlena Tanese de Souza Christiano Kennedy Michael A. Tadros Shaheer Auer Rebecca C. 《Annals of surgical oncology》2022,29(12):7410-7420
Annals of Surgical Oncology - Surgery results in severe impairment of natural killer (NK) cell cytotoxicity (NKC) and activity (NKA, cytokine secretion), and a dramatic drop in arginine levels.... 相似文献
84.
85.
Paulina Krzyszczyk Hwan June Kang Suneel Kumar Yixin Meng Maurice D. O'Reggio Kishan Patel Ivan S. Pires Martin L. Yarmush Rene S. Schloss Andre F. Palmer Franois Berthiaume 《Wound repair and regeneration》2020,28(4):493-505
Nonhealing wounds possess elevated numbers of pro‐inflammatory M1 macrophages, which fail to transition to anti‐inflammatory M2 phenotypes that promote healing. Hemoglobin (Hb) and haptoglobin (Hp) proteins, when complexed (Hb‐Hp), can elicit M2‐like macrophages through the heme oxygenase‐1 (HO‐1) pathway. Despite the fact that nonhealing wounds are chronically inflamed, previous studies have focused on non‐inflammatory systems, and do not thoroughly compare the effects of complexed vs individual proteins. We aimed to investigate the effect of Hb/Hp treatments on macrophage phenotype in an inflammatory, lipopolysaccharide (LPS)‐stimulated environment, similar to chronic wounds. Human M1 macrophages were cultured in vitro and stimulated with LPS. Concurrently, Hp, Hb, or Hb‐Hp complexes were delivered. The next day, 27 proteins related to inflammation were measured in the supernatants. Hp treatment decreased a majority of inflammatory factors, Hb increased many, and Hb‐Hp had intermediate trends, indicating that Hp attenuated overall inflammation to the greatest extent. From this data, Ingenuity Pathway Analysis software identified high motility group box 1 (HMGB1) as a key canonical pathway—strongly down‐regulated from Hp, strongly up‐regulated from Hb, and slightly activated from Hb‐Hp. HMGB1 measurements in macrophage supernatants confirmed this trend. In vivo results in diabetic mice with biopsy punch wounds demonstrated accelerated wound closure with Hp treatment, and delayed wound closure with Hb treatment. This work specifically studied Hb/Hp effects on macrophages in a highly inflammatory environment relevant to chronic wound healing. Results show that Hp—and not Hb‐Hp, which is known to be superior in noninflammatory conditions—reduces inflammation in LPS‐stimulated macrophages, and HMGB1 signaling is also implicated. Overall, Hp treatment on M1 macrophages in vitro reduced the inflammatory secretion profile, and also exhibited benefits in in silico and in vivo wound‐healing models. 相似文献
86.
Thierry Andre Mayur Amonkar Josephine M Norquist Kai-Keen Shiu Tae Won Kim Benny Vittrup Jensen Lars Henrik Jensen Cornelis J A Punt Denis Smith Rocio Garcia-Carbonero Isabel Sevilla Christelle De La Fouchardiere Fernando Rivera Elena Elez Luis A Diaz Takayuki Yoshino Eric Van Cutsem Ping Yang Dung T Le 《The lancet oncology》2021,22(5):665-677
87.
88.
Hope S. Rugo Jens Huober Jos A. GarcíaSenz Norikazu Masuda Joo Hyuk Sohn Valerie A.M. Andre Susana Barriga Joanne Cox Matthew Goetz 《The oncologist》2021,26(1):e53-e65
BackgroundAbemaciclib demonstrated efficacy in hormone receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer. Here we provide a comprehensive summary of the most common adverse events (AEs), their management, and whether AEs or dose reductions influenced progression‐free survival (PFS), in the MONARCH 2 and 3 trials.Materials and MethodsIncidence of the most clinically relevant AEs, management, and outcomes were summarized. Time‐dependent covariate analyses examined the impact of dose reductions on PFS. PFS was estimated for patients with and without early onset of diarrhea or neutropenia.ResultsThe most frequently reported AE was diarrhea, with clinically significant diarrhea (grade ≥2) reported for 42.8% of patients taking abemaciclib. Median time to onset was 1 week, and duration ranged from 6 to 12 days, depending on grade and study. Diarrhea was adequately managed by antidiarrheal medication (72.8%), dose omissions (17.3%), and reductions (16.7%). The highest rates of grade ≥2 diarrhea were observed in the first cycles and decreased in subsequent cycles. Neutropenia (grade ≥3) occurred in 25.4% of abemaciclib‐treated patients. Neutropenia resolved with dose omissions (16.8%) and/or dose reductions (11.2%). Incidence of febrile neutropenia (0.7%) or other relevant grade ≥3 hematological events (<9%) was low. Venous thromboembolic events (5.3%) were primarily treated with anticoagulants. Interstitial lung disease/pneumonitis (3.4%) was treated with corticosteroids and/or antibiotics. PFS benefit of abemaciclib was not impacted by dose reductions or early onset of toxicities.ConclusionAbemaciclib was generally well tolerated. The most common AEs were effectively managed by supportive medications, and/or dose adjustments, with no detriment to PFS.Implications for PracticeTreatment with abemaciclib plus fulvestrant or nonsteroidal aromatase inhibitors is generally well tolerated in patients with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer. In MONARCH 2 and MONARCH 3, any‐grade diarrhea and grade ≥3 neutropenia were effectively managed with supportive medication and/or dose adjustment. Venous thromboembolic events were treated with anticoagulants and did not often require treatment discontinuation. Interstitial lung disease/pneumonitis was infrequent and treated with corticosteroids and/or antibiotics. Clinicians should be aware of and implement management strategies, including dose adjustments according to local labels, for commonly occurring and serious adverse events to ensure continued treatment and optimize clinical benefit/risk ratio. 相似文献
89.
Travison TG Araujo AB O'Donnell AB Kupelian V McKinlay JB 《The Journal of clinical endocrinology and metabolism》2007,92(1):196-202
CONTEXT: Age-specific estimates of mean testosterone (T) concentrations appear to vary by year of observation and by birth cohort, and estimates of longitudinal declines in T typically outstrip cross-sectional decreases. These observations motivate a hypothesis of a population-level decrease in T over calendar time, independent of chronological aging. OBJECTIVE: The goal of this study was to establish the magnitude of population-level changes in serum T concentrations and the degree to which they are explained by secular changes in relative weight and other factors. DESIGN: We describe a prospective cohort study of health and endocrine functioning in randomly selected men of age 45-79 yr. We provide three data collection waves: baseline (T1: 1987-1999) and two follow-ups (T2: 1995-1997, T3: 2002-2004). SETTING: This was an observational study of randomly selected men residing in greater Boston, Massachusetts. PARTICIPANTS: Data obtained from 1374, 906, and 489 men at T1, T2, and T3, respectively, totaling 2769 observations taken on 1532 men. MAIN OUTCOME MEASURES: The main outcome measures were serum total T and calculated bioavailable T. RESULTS: We observe a substantial age-independent decline in T that does not appear to be attributable to observed changes in explanatory factors, including health and lifestyle characteristics such as smoking and obesity. The estimated population-level declines are greater in magnitude than the cross-sectional declines in T typically associated with age. CONCLUSIONS: These results indicate that recent years have seen a substantial, and as yet unrecognized, age-independent population-level decrease in T in American men, potentially attributable to birth cohort differences or to health or environmental effects not captured in observed data. 相似文献
90.
乙型肝炎病毒基因的整合机制及对宿主的影响 总被引:1,自引:0,他引:1
乙型肝炎病毒是导致慢性肝炎、肝纤维化、肝细胞癌的主要病因,目前认为乙型肝炎病毒基因整合在其致病机制中具有重要作用,本文试就该领域内目前研究成果做一综述. 相似文献